BACKGROUND: Clinical studies play a pivotal role in the development of new pharmaceutical drugs. Before newly developed active substances can be put on the market, the law requires that they be tested in a large number of clinical trials. The initiators of these trials are usually study groups (publicly funded trials) or the pharmaceutical industry, which often supplies the drugs for clinical research in hospitals. There is reason to believe that hospital administrators could make cost savings on drugs. PURPOSE: The purpose of this article is to quantify drug cost savings in hospitals related to clinical trials and to examine the relationship between researchers and hospital administrators with respect to clinical trials. METHODOLOGY/APPROACH: We analyzed 88 clinical trials in oncology including 29 researchers in 11 hospitals in Germany from 2002 through 2005. We also interviewed researchers and hospital administrators concerning their attitude toward these clinical trials. We propose that hospital administrators tend to focus on the economics of conducting clinical trials. FINDINGS: The results showed a drug cost saving potential of US $6.7 million (euro5.1 million) in 11 hospitals from 2002 through 2005 and an actual cost saving of US $2.0 million (euro1.5 million). The hospital administrators underestimated the difficulties that researchers experienced because of lack of personnel resources when conducting clinical trials. PRACTICE IMPLICATIONS: The hospital administrator has a financial incentive to provide internal conditions in the hospital that facilitate incentives for researchers to become involved in clinical trials. We suggest supporting researchers actively in research with additional human resources (study nurses, etc.). We propose that this would result in a higher number of patients taking part and in more clinical trials. Consequently, higher drug cost savings could also be realized.
BACKGROUND: Clinical studies play a pivotal role in the development of new pharmaceutical drugs. Before newly developed active substances can be put on the market, the law requires that they be tested in a large number of clinical trials. The initiators of these trials are usually study groups (publicly funded trials) or the pharmaceutical industry, which often supplies the drugs for clinical research in hospitals. There is reason to believe that hospital administrators could make cost savings on drugs. PURPOSE: The purpose of this article is to quantify drug cost savings in hospitals related to clinical trials and to examine the relationship between researchers and hospital administrators with respect to clinical trials. METHODOLOGY/APPROACH: We analyzed 88 clinical trials in oncology including 29 researchers in 11 hospitals in Germany from 2002 through 2005. We also interviewed researchers and hospital administrators concerning their attitude toward these clinical trials. We propose that hospital administrators tend to focus on the economics of conducting clinical trials. FINDINGS: The results showed a drug cost saving potential of US $6.7 million (euro5.1 million) in 11 hospitals from 2002 through 2005 and an actual cost saving of US $2.0 million (euro1.5 million). The hospital administrators underestimated the difficulties that researchers experienced because of lack of personnel resources when conducting clinical trials. PRACTICE IMPLICATIONS: The hospital administrator has a financial incentive to provide internal conditions in the hospital that facilitate incentives for researchers to become involved in clinical trials. We suggest supporting researchers actively in research with additional human resources (study nurses, etc.). We propose that this would result in a higher number of patients taking part and in more clinical trials. Consequently, higher drug cost savings could also be realized.
Authors: Francesca D'Ambrosio; Gianfranco De Feo; Gerardo Botti; Arturo Capasso; Sandro Pignata; Piera Maiolino; Maria Triassi; Antonio Nardone; Franco Perrone; Michela Piezzo; Antonio Maria Grimaldi; Ida Palazzo; Immacolata De Stasio; Roberta D'Aniello; Alessandro Morabito; Giacomo Pascarella Journal: BMC Health Serv Res Date: 2020-11-26 Impact factor: 2.655